EPHB2 a possible advance in mesothelioma treatment

September 10th, 2013

The Journal of Thoracic Oncology has published the results of a study, which found that silencing the EPHB2 receptor in the body increased the process of removing cancerous cells. The results showed a potential novel treatment of pleural mesothelioma cancer, which often develops after asbestos exposure.

The potential treatment is good news for mesothelioma patients, who only have one Food and Drug Administration-approved form of treatment. More than 4,000 people in the United States are affected by mesothelioma cancer every year.

Many mesothelioma patients develop the cancer after being exposed to asbestos while working industrial jobs. Thousands of mesothelioma lawsuits have been filed against companies who knowingly exposed their employees to the carcinogenic substance.


Contact Us Today for a Free Consultation.

    MesotheliomaAsbestosisLung cancerSilicosis

    [anr_nocaptcha g-recaptcha-response]

    *Required fields